NO20000822L - Substituerte 4-okso-3-karboksamider som GABA- hjernereseptorligander - Google Patents

Substituerte 4-okso-3-karboksamider som GABA- hjernereseptorligander

Info

Publication number
NO20000822L
NO20000822L NO20000822A NO20000822A NO20000822L NO 20000822 L NO20000822 L NO 20000822L NO 20000822 A NO20000822 A NO 20000822A NO 20000822 A NO20000822 A NO 20000822A NO 20000822 L NO20000822 L NO 20000822L
Authority
NO
Norway
Prior art keywords
substituted
agonists
carboxamides
oxo
receptor ligands
Prior art date
Application number
NO20000822A
Other languages
English (en)
Other versions
NO20000822D0 (no
Inventor
Pamela Albaugh
Robert W Desimone
Gang Liu
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of NO20000822D0 publication Critical patent/NO20000822D0/no
Publication of NO20000822L publication Critical patent/NO20000822L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse omfatter strukturer med Formel (I) eller de farmasøytisk akseptable ikke-toksiske saltene derav, hvori: X er hydrogen, halogen, (u)substituert alkyl, (u)substituert alkoksy eller amino; og Y er (u)substituert alkyl, aryl eller heteroaryl, hvilke forbindelser er i høy grad selektive agonister, antagonister eller inverse agonister for GABAa hjernereseptorer eller pro-legemidler av agonister, antagonister eller inverse agonister for GABAa hjernereseptorer. Disse forbindelsene er nyttige for diagnose og behandling av angst, Down Syndrom, søvnforstyrrelse, kognitive forstyrrelser samt anfall og overdoser med benzodiazepin-legemidler og for forsterkning, av våkenhet.
NO20000822A 1997-08-25 2000-02-18 Substituerte 4-okso-3-karboksamider som GABA- hjernereseptorligander NO20000822L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (2)

Publication Number Publication Date
NO20000822D0 NO20000822D0 (no) 2000-02-18
NO20000822L true NO20000822L (no) 2000-04-13

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000822A NO20000822L (no) 1997-08-25 2000-02-18 Substituerte 4-okso-3-karboksamider som GABA- hjernereseptorligander

Country Status (24)

Country Link
EP (1) EP1007526A1 (no)
JP (1) JP2001514181A (no)
KR (1) KR20010023313A (no)
CN (1) CN1268136A (no)
AP (1) AP2000001742A0 (no)
AU (1) AU753800B2 (no)
BG (1) BG104192A (no)
BR (1) BR9811362A (no)
CA (1) CA2301599C (no)
EG (1) EG21717A (no)
HU (1) HUP0003258A3 (no)
IL (1) IL134291A0 (no)
IS (1) IS5382A (no)
LV (1) LV12539B (no)
NO (1) NO20000822L (no)
NZ (1) NZ502548A (no)
OA (1) OA11293A (no)
PE (1) PE130999A1 (no)
PL (1) PL338783A1 (no)
SI (1) SI20270A (no)
SK (1) SK2162000A3 (no)
TW (1) TW574221B (no)
WO (1) WO1999010347A1 (no)
YU (1) YU10500A (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4818000A (en) * 1999-05-06 2000-11-21 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
ES2287170T3 (es) 2000-10-12 2007-12-16 MERCK & CO., INC. Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2002030930A2 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
SK10752003A3 (sk) * 2001-03-01 2004-08-03 Pfizer Products Inc. Použitie inverzných agonistov GABAA v kombinácii s parciálnymi agonistami receptora nikotínu, estrogénom, selektívnymi modulátormi estrogénu alebo vitamínom E pri liečení kognitívnych porúch
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
ATE370948T1 (de) 2002-01-17 2007-09-15 Merck & Co Inc Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
WO2003077850A2 (en) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
PL2074123T3 (pl) * 2006-10-16 2013-04-30 Bionomics Ltd Nowe związki o działaniu przeciwlękowym
ES2610508T3 (es) * 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204813A1 (es) * 1972-05-08 1976-03-05 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampilicina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
AU753800B2 (en) 2002-10-31
BG104192A (en) 2001-05-31
TW574221B (en) 2004-02-01
SI20270A (sl) 2000-12-31
PL338783A1 (en) 2000-11-20
LV12539B (en) 2001-01-20
CA2301599C (en) 2003-03-25
CA2301599A1 (en) 1999-03-04
JP2001514181A (ja) 2001-09-11
PE130999A1 (es) 1999-12-16
BR9811362A (pt) 2000-08-22
NZ502548A (en) 2002-06-28
LV12539A (en) 2000-10-20
NO20000822D0 (no) 2000-02-18
IS5382A (is) 2000-02-22
OA11293A (en) 2002-11-19
HUP0003258A2 (en) 2001-03-28
YU10500A (sh) 2002-10-18
AP2000001742A0 (en) 2000-02-24
SK2162000A3 (en) 2001-03-12
IL134291A0 (en) 2001-04-30
WO1999010347A1 (en) 1999-03-04
KR20010023313A (ko) 2001-03-26
EP1007526A1 (en) 2000-06-14
EG21717A (en) 2002-02-27
HUP0003258A3 (en) 2001-05-28
AU9117398A (en) 1999-03-16
CN1268136A (zh) 2000-09-27

Similar Documents

Publication Publication Date Title
NO20000822L (no) Substituerte 4-okso-3-karboksamider som GABA- hjernereseptorligander
CA2175204A1 (en) Certain Fused Pyrrolecarboxanilides; a New Class of GABA Brain Receptor Ligands
HUP0000079A2 (hu) Indán- és dihidroindolszármazékok
DK0555391T3 (da) Visse imidazoquinoxaliner; en ny klasse GABA-receptorligander i hjernen
MX9805701A (es) Nuevas pirrolcarboxamidas fusionadas; una nueva clase de ligandos del receptor cerebral gaba.
DE69636670D1 (de) Benzimidazolverbindungen und ihre verwendung als gaba a receptor komplex modulatoren
US20030171395A1 (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
WO1999043660A1 (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands
DE69925462D1 (de) Substituierte cycloalkyl-4-oxonicotinische karboxamide; gaba gehirn-rezeptorligande
HUP0303630A2 (hu) Imidazo-pirimidin-származékok, mint GABA receptorok ligandumai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69609413D1 (de) BENZIMIDAZOLVERBINDUNGEN UND IHRE VERWENDUNG ALS MODULATOREN DES GABAa-REZEPTORKOMPLEXES
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
AU2321597A (en) Novel imidazo{1,5-c}quinazolines; a new class of gaba brain receptor ligands
EP4025211A1 (en) Methods of treating epilepsy using the same
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
BR0009539A (pt) composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
ATE482931T1 (de) Somatostatinrezeptor-1- und/oder -4-selektive agonisten und antagonisten
DE69926378D1 (de) Oxo-pyridoimidazol-carboxamide: gaba-rezeptor-liganden im gehirn
TH42836A (th) ซับสทิทิวเทด 4-ออกโซ-แนฟธิริดีน-3-คาร์บอกแซมีด; gaba เบรน รีเซปเตอร์ ลิแกนด์
CA2249562A1 (en) Certain fused pyrrolecarboxamides as gaba brain receptor ligands
BR112019028078A2 (pt) derivados de 2-oxo-1,3-oxazolidinil imidazotiadiazol
AR007742A1 (es) Pirrolcarboxanilidas fusionadas; una nueva clase de ligandos receptores gaba del cerebro.
TH35993A (th) ฟิวส์ พิร์โรลคาร์บอกแซนิไลด์
BR9807840A (pt) Derivados de 4-aminoalcóxi-1,3-dihidrobenzoimidazol-2-tionas, sua preparação e seu uso como agonistas de auto-receptor de dopamina (d2)
MXPA01006351A (en) Diphenylurea compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application